Genomics CEO Says Vertex R&D Pact, £25m Series B Secure Its Viability
Executive Summary
The Oxford biotech raised £25m from investors and inked a collaboration with Vertex that's probably worth tens of millions of pounds, maybe much more. The founder and CEO of Genomics PLC tells Scrip the four-year-old company will also seek other pharma alliances.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q3 2018
Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.
Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Need a specific report? 1000+ reports available
Buy Reports